

Date: 22 Feb, 2018

To,
Listing Department,
Dept. of Corporate Services,
Bombay Stock Exchange Limited,
P.J. Towers, Dalal Street, Fort,
Mumbai: 400 001.

To,
General Manager,
National Stock Exchange of India Ltd.,
Exchange Plaza, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai: 400 051.

Dear Sir/Madam,

Ref .:-

Scrip Code - 532908

Scrip ID-SHARONBIO

Sub:-

Financial Results for the quarter and six months ended September 30,2017.

Pursuant to Regulation 33 of the SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015, we would like to intimate the exchange that Resolution Professional on 22 February, 2018 has considered and approved the following:

 The Standalone Unaudited Financial Results of the Company with Limited Review Report for the quarter and six months ended September 30, 2017.

The meeting of Resolution Professional held today, commenced at 3:00 pm and concluded at 7:50 pm.

Kindly find the same for your record & acknowledge the receipt for the same.

Thanking You,

Yours faithfully,

For Sharon Bio-Medicine Limited

Deepali Bhatia

Company Secretary & Compliance officer

Encl.: a/a

Adm. Off.: 312, C Wing, BSEL Tech Park, Sector - 30(A), Vashi, Navi Mumbai - 400 705. Tel.: 91 22 - 67944000, Fax: 91 22 - 67944001

www.sharonbio.com

CIN NO. L24110MH1989PLC052251

Caring for relationships



Place : Mumbai.

Date: February 22, 2018



An ISO-9001:2000 Certified Company

## Extract of Statement of Standalone Unaudited Financial Results for the Quarter and Six Months ended September 30, 2017

(₹ in Lacs)

( < in Lac			
PARTICULARS	Quarter Ended 30/09/2017	Quarter Ended 30/09/2016	Six Months Ended 30/09/2017
	Unaudited	Unaudited	Unaudited
Total income from operations	3,122.56	4,639.87	5,318.08
Net Profit / (Loss) for the period (Before Tax, Exceptional			
and/or Extraordinary items)	38.01	68.92	(486.53)
Net Profit / (Loss) for the period before tax (after			
Exceptional and/or Extraordinary items)	37.91	(1,895.74)	(9,524.38)
Net Profit / (Loss) for the period after tax (after Exceptional	07.04	(4.000.04)	(0.504.00)
and/or Extraordinary items)	37.91	(1,082.94)	(9,524.38)
Total Comprehensive Income for the period [Comprising			
Profit/ (Loss) for the period (after tax) and Other	34.01	(1,086.84)	(9,532.18)
Comprehensive Income (after tax)]			, , , , ,
Paid up Equity Share Capital (Face Value of Rs.2/- each)	2,378.71	2,378.71	2,378.71
Earnings Per share (before extraordinary items)	0.02	(0.01)	(0.01)
(of 2/- each) Basic	0.03	(0.91)	(8.01)
Earnings Per share (after extraordinary items) (of 2/- each) Diluted	0.03	(0.91)	(8.01)
(OI 21- eacil) Diluteu	0.03	(0.91)	(0.01)

**Note:** The above is an extract of the detailed format of Standalone Unaudited Financial Results for the Quarter and Six Months Ended September 30, 2017 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Standalone Uaudited Financial Results for the Quarter and Six Months ended September 30, 2017 are available on the Stock Exchange websites. (www.bseindia.com/www.nseindia.com) and Company's website www.sharonbio.com.

For Sharon Bio-Medicine Ltd.

SD/-

Savita Gowda Managing Director. Dinkar Venkatasubramanian Resolution Professional IP Registration no. IBBI/IPA-001/

IP-P00003/2016-17/10011

REGISTERED OFFICE & WORKS: W-34 & 34/1, MIDC, Taloja,

Dist.Raigad. Maharashtra (India).

CORP.: C-310/312, BSEL Tech Park, Opp. Vashi-Railway Station, Navi Mumbai – 400 703.

E-mail: investor\_complaints@sharonbio.com, Website: www.sharonbio.com